Open-label, Multicenter, Dose-escalation/Expansion Phase Ib Study to Evaluate Safety, Pharmacokinetics, and Activity of BET Inhibitor RO6870810, Given as Mono- and Combination Therapy to Patients With Advanced Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 02 Nov 2018
At a glance
- Drugs Daratumumab (Primary) ; RG 6146 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 25 Oct 2018 Planned End Date changed from 19 Mar 2019 to 25 Jun 2019.
- 25 Oct 2018 Planned primary completion date changed from 19 Mar 2019 to 25 Jun 2019.
- 28 May 2018 Planned End Date changed from 15 Jan 2020 to 19 Mar 2019.